2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide,
GDC-0032,
GDC0032,
RO5537381,
taselisib,
Taselisib,
GDC-0032,
1282512-48-4,
GDC 0032,
2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide,
RG7604,
UNII-L08J2O299M,
CHEMBL2387080,
GDC0032,
L08J2O299M,
RG 7604,
RG-7604,
Taselisib [INN],
2-Methyl-2-(4-{2-[3-Methyl-1-(Propan-2-Yl)-1h-1,2,4-Triazol-5-Yl]-5,6-Dihydroimidazo[1,2-D][1,4]benzoxazepin-9-Yl}-1h-Pyrazol-1-Yl)propanamide,
Taselisib [USAN:INN],
Taselisib (GDC 0032),
GTPL7794,
SCHEMBL1485247,
DTXSID00155842,
SYN1202,
BEUQXVWXFDOSAQ-UHFFFAOYSA-N,
BCP09253,
EX-A1581,
BDBM50434806,
MFCD26142641,
s7103,
ZINC68267049,
Taselisib pound GDC-0032 pound(c),
AKOS026750303,
CS-1817,
DB12108,
GDC-0032, Taselisib; RG-7604,
SB16576,
KS-00001D74,
NCGC00387039-02,
AK343038,
AS-10662,
HY-13898,
QC-11626,
A12831,
Z-3154,
J-690119,
1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-alpha,alpha-dimethyl-,
2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide(GDC-0032),
3-({[(3R,5R)-3-Butyl-3-ethyl-7-methoxy-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic aci d,
4-[5,6-Dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-|A,|A-dimethyl-1H-pyrazole-1-acetamide,
D0UP1Z,
C24H28N8O2,
ACN-036695,
B1047,
GDC-0032, 98%, a potent beta-sparing small molecule inhibitor of PI3K - 25MG 25mg,
1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-alpha, alpha-dimethyl-,
4-[5,6-Dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-alpha,alpha-dimethyl-1H-pyrazole-1-acetamide,